Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To compare the systemic exposure for intranasal mometasone furoate (MF) and fluticasone propionate (FP) aqueous nasal sprays (ANS) in terms of serum and urinary cortisol parameters and plasma pharmacokinetics.
Twelve healthy subjects completed this three-way, cross-over study. They received FPANS (50 μg/spray), MFANS (50 μg/spray) or placebo ANS, eight sprays per nostril every 8 h for 4 days. Cortisol measurements were made at baseline and day 4. FP and MF plasma concentrations were also measured on day 4.
MFANS produced similar mean plasma AUC (123 pmol/l h) to FPANS (112 pmol/l h). Despite the use of high doses, necessary to generate adequate pharmacokinetic data, only minor reductions in cortisol parameters were found, with no difference between FPANS and MFANS.
FP and MF have similar and very low systemic bioavailability when administered intranasally using a high-dose regimen. It is therefore unlikely that therapeutic doses of intranasal FP or MF will produce dissimilar or significant degrees of systemic exposure or systemic effects.
- Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays
European Journal of Clinical Pharmacology
Volume 60, Issue 4 , pp 265-268
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Fluticasone propionate
- Mometasone furoate
- Nasal bioavailability
- Industry Sectors
- Author Affiliations
- 1. GlaxoSmithKline Research & Development, Clinical Pharmacology & Discovery Medicine, Greenford Road, Greenford, Middlesex, UB6 0HE, UK
- 2. GlaxoSmithKline Research & Development, Research Triangle Park, NC, USA
- 3. GlaxoSmithKline Research & Development, Park Road, Ware, UK